RTTNews BiotechQwen · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 16:09:24·⟳ 抓取 16:15:14 +5m50s·⚡ 决策 09-14 16:21:10 +5m56s·43.1 天前
强生 RYBREVANT 联合化疗在 PAPILLON 最终分析中报告 EGFR 20外显子插入 NSCLC 中位 OS 34.3 个月（未校正 HR 0.87、P=0.307 未达显著），为已获批适应症的确认性数据
状态迁移只是「已获批并已成一线标准的方案 → 补充确认性最终 OS 描述性数据」，没有新适应症、新获批、新报销准入或收入/指引变化；未校正 OS HR 0.87、P=0.307 本身未达显著，标题所称「新标杆」主要来自校正交叉后的分析。主体 JNJ 市值 6400 亿美元、20 日实现波动仅 1.45%/日，exon20ins 一线小人群带来的 NPV 增量相对市值可忽略；竞争侧（迪哲医药、AZN、Genmab）的竞争格局在 2026 年 6 月研报中已被充分讨论，本次不构成新的实质净损害，做空红线（强空催化 + confidence≥4）第①条不满足。故全链 AVOID，且不输出 risk_signals。
📄 原文RTTNews Biotech↗ 原文
J&J's RYBREVANT Plus Chemotherapy Sets New Benchmark In EGFR Exon 20 Insertion NSCLC Survival
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 强生 Johnson & Johnson（JNJ.US）
超大市值（约 6400 亿美元）主标的的软/确认性催化：amivantamab+化疗在一线 EGFR exon20ins 已获批并已是标准治疗，本次仅为方案预设最终 OS 分析（34.3 vs 27.9 个月，未校正 HR 0.87、P=0.307 未达显著，校正交叉后 HR 0.57），无新适应症、新获批、报销准入或指引变化；exon20ins 仅占 NSCLC 约 1–2%，增量 NPV 相对市值可忽略，1–3 日窗口无可交易 edge。且近 5 日 -4.62%、13…
不做 迪哲医药-U（688192.SH）
作为同适应症口服竞品（舒沃替尼）的竞争侧映射，不满足做空红线第①条：J&J 数据的竞争压力在 PAPILLON 主要 PFS 结果与 2026-06 研报竞争格局梳理中已被市场消化，本次 OS 未校正分析未达显著、且 76% 交叉严重混淆，不改变舒沃替尼口服单药的差异化定位；公司已将全球权益授权阿斯利康（6 亿美元首付款），短期业绩与该竞品数据脱钩，并正处于 9/12–15 WCLC 自有数据披露窗口，做空风险回报差。做多同样无本事件催化，故不做。
不做 AstraZeneca（AZN.US）
作为舒沃替尼全球权益受让方仅承受边际竞争背景影响，竞品 OS 未达显著且格局无变化，对 AZ 收入、指引与估值无实质增量，无方向与 edge。
不做 Genmab（GMAB.US）
市场普遍认知其为 amivantamab 的 DuoBody 平台特许权方（本轮 Web 检索降级，具体 royalty 条款与比例未核验），但确认性 OS 数据不改变已获批产品的销售轨迹、权益比例或指引，缺乏可验证的增量收入催化，且因果敞口未坐实，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
强生 RYBREVANT+化疗在 PAPILLON 最终 OS 分析中报告 34.3 vs 27.9 个月，但这是已获批、已是一线标准方案的确认性数据，未校正 HR 0.87（P=0.307）未达显著，无新适应症或指引变化。相对 6400 亿美元市值无 materiality，竞品侧竞争格局亦早已被市场消化，全链不做。
🔎 新鲜度:最早出现 2026-09-14 · 扩散 low · price-in 风险 medium ↗
消息传播链
- 本信号首读来源，转述 J&J 公告并给出完整数据（OS 34.3 vs 27.9 个月、HR 0.87/P=0.307、校正 HR 0.57、PFS2 28.3 vs 17.5）。JNJ 官方新闻稿链接本轮未能取得：Web 搜索三次查询均返回与该事件无关的结果（字母释义、建模网站、游戏站等），故一手源标记为未核验、仅记为转述。市场反应:JNJ 盘前（04:08 ET 报价）268.67 美元 +1.16%，成交仅 809 股/21.7 万美元，夜盘 1164 股，属薄量漂移，不构成有效重定价
- 2026 年世界肺癌大会（WCLC）于 9 月 12–15 日在首尔举行，迪哲医药舒沃替尼两项 NSCLC 数据以壁报展示；本次 J&J 数据披露时点与该会议窗口重合，说明属会议期常规学术披露节奏，而非突发性商业利好，市场对该窗口内同类数据已有预期。
主要风险
- 本轮 Web 搜索服务返回大量不相关结果，未能核验 JNJ 官方新闻稿原文与是否伴随监管/标签动作；若实际同时有新适应症申报或指南升级，materiality 判断需重估（但相对 JNJ 市值仍难构成短线催化）
- JNJ 盘前报 268.67 美元（+1.16%）仅对应 809 股成交，属夜盘/盘前薄量噪声，不可作为该消息已被市场重定价的证据
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-06-23 · 影响 weakens
内资研报（2026-06）已明确记录：PAPILLON 主要分析（中位 PFS 11.4 vs 6.7 个月，HR 0.40，P<0.0001）已确立 amivantamab+化疗一线地位并支撑全球批准，exon20ins 竞争格局（舒沃替尼/埃万妥单抗/伏美替尼/安达艾替尼）早被系统梳理，莫博赛替尼一线 EXCLAIM-2 失败后已全球撤市——即本次 OS 属既有认知的确认，而非新预期差
检索:amivantamab RYBREVANT 销售额 EGFR exon 20 insertion NSCLC PAPILLON 竞争格局 原文 ↗ - 做空前查反向 · 来源 kb_search · 日期 2026-07-14 · 影响 invalidates
迪哲医药 2026-07-14 将舒沃替尼全球独家权益授权阿斯利康，获 6 亿美元不可返还首付款、总额最高 15 亿美元+销售分级特许权；其一线 LBA 数据（全球 300+ 例头对头化疗 HR 0.65，DOR/ORR 均显著提升）已披露，差异化优势为口服单药 vs 双抗需联合化疗注射且毒性较强，并即将在美申报——竞品确认性 OS 数据不改变其权益结构与临床定位
检索:迪哲医药 舒沃替尼 EGFR 20外显子插入 一线 竞争 amivantamab PAPILLON 原文 ↗ - 做多前查反向 · 来源 stock_quote · 日期 2026-09-14 · 影响 weakens
JNJ 近 5 日 -4.62%、13 周轨迹由 119 回落至 113、距 60 日高 -5.51%，量比 0.75；消息前无抢跑放量，但下行趋势本身对做多构成逆风，且盘前 +1.16% 仅 809 股，属薄量漂移而非承接确认
检索:JNJ.US 近期股价轨迹与事件前异动
先例如何影响了这次决策
对本次决策的影响:先例缺失未改变结论：AVOID 的依据是状态迁移无增量（无新获批/新适应症/指引变化）+ 6400 亿美元市值下的 materiality 缺失 + 竞争格局已被市场消化，而非幅度校准
方向:无可用先例统计支撑；但从机制上判断，超大市值药企在已获批适应症上的确认性最终 OS 数据属低 surprise、低 materiality 类别，历史上通常无显著股价反应
涨幅量级:未做幅度校准：本轮无任何 ENTER 腿，tp/sl 数字不进入决策，幅度校准不具决策相关性
形态:无法评估见光死/高开低走：JNJ 盘前仅 809 股成交的 +1.16% 属噪声，不是事件驱动的价格形态
工具执行结果 · 成功 14 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 52 ms
{"result": "search_processed_events:agent query=`j&j amivantamab egfr exon 20 insertion nsclc | johnson johnson 34.3 months median os | rybrevant chemotherapy final analysis | rybrevant papillon overall survival`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选， - fetch_decision_experience 成功 stock_tools HTTP · 19 ms
{ - web_search 成功 Bing RSS · 306 ms
Bing RSS 搜索结果（原始查询:J&J press release RYBREVANT PAPILLON final overall survival EGFR exon 20 insertion 34.3 months） - web_search 成功 Bing RSS · 259 ms
Bing RSS 搜索结果（原始查询:Genmab royalty amivantamab RYBREVANT DuoBody sales contribution） - web_search 成功 Bing RSS · 271 ms
Bing RSS 搜索结果（原始查询:迪哲医药 舒沃替尼 EGFR exon 20 insertion 一线 竞争 amivantamab PAPILLON） - stock_quote 成功 stock_tools HTTP · 592 ms
{ - web_search 成功 Bing RSS · 283 ms
Bing RSS 搜索结果（原始查询:RYBREVANT PAPILLON final overall survival analysis September 2026 press release Johnson Johnson） - web_search 成功 Bing RSS · 243 ms
Bing RSS 搜索结果（原始查询:"RYBREVANT" EGFR exon 20 insertion overall survival 34.3 months 2026） - kb_search 成功 stock_tools HTTP · 4,091 ms
{ - kb_search 成功 stock_tools HTTP · 2,844 ms
{ - web_search 成功 Bing RSS · 262 ms
Bing RSS 搜索结果（原始查询:Johnson & Johnson newsroom RYBREVANT longest median overall survival exon 20 insertion lung cancer） - web_search 成功 Bing RSS · 287 ms
Bing RSS 搜索结果（原始查询:PAPILLON trial amivantamab overall survival final analysis presented conference 2026 exon20ins） - kb_search 成功 stock_tools HTTP · 642 ms
{ - web_search 成功 Bing RSS · 572 ms
Bing RSS 搜索结果（原始查询:Rybrevant overall survival news JNJ stock）
原文全文
展开原文 · 10,391 字
J&J's RYBREVANT Plus Chemotherapy Sets New Benchmark In EGFR Exon 20 Insertion NSCLC Survival
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
J&J's RYBREVANT Plus Chemotherapy Sets New Benchmark In EGFR Exon 20 Insertion NSCLC Survival
By
TajSabreen Ahamed
✉
Published:
9/14/2026 4:09 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Johnson & Johnson (
JNJ
) announced that its bispecific antibody RYBREVANT, when combined with chemotherapy, achieved the longest reported median overall survival in patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC).
Patients receiving the combination achieved a median overall survival of 34.3 months, compared with 27.9 months for chemotherapy alone. Even though 76% of patients in the chemotherapy arm crossed over to second-line RYBREVANT after disease progression, the combination still extended survival by more than six months. These results represent the longest reported median OS in this population, nearly double historical survival expectations of 16-24 months, with five-year survival rates about 8%.
Durable Benefit and Differentiated Mechanism
RYBREVANT is the first-in-class bispecific antibody designed to dual-target EGFR and MET, two key drivers of tumor growth and treatment resistance, while also engaging the immune system. It is already approved across multiple EGFR- mutations NSCLC settings, including exon 20 insertion mutations.
Dr. Chul Kim of MedStar Georgetown University Hospital highlighted that the findings represent a meaningful advance for patients with limited treatment options, reinforcing RYBREVANT's role as a new standard in the first-line setting.
Detailed Overall Survival & Progression-Free Survival Findings
In the protocol-specified final analysis, RYBREVANT plus chemotherapy achieved:
-Median OS: 34.3 months vs. 27.9 months (HR 0.87; Cl 0.66-1.14; P=0.307)
-Adjusted OS (accounting for crossover): 43% reduction in risk of death (HR 0.57; Cl 0.39-0.82; nominal P=0.003)
-PFS2: Extended by more than 10 months (28.3 vs. 17.5 months; HR 0.59; P<0.0001)
-Treatment durability: 12% of patients remained on first-line therapy at cutoff vs. 0% in chemotherapy arm.
-Patient-reported outcomes: Delayed worsening of key lung cancer symptoms vs. chemotherapy alone.
These findings build on primary PAPILLON analysis, which previously demonstrated a clinically meaningful 60% improvement in progression-free survival, supporting global approvals.
Safety Profile
The safety profile of RYBREVANT plus chemotherapy was consistent with earlier studies, with no new safety signals observed.
Common treatment-related adverse events (greater than or equal to 30%) include paronychia, neutropenia, and rash.
About the PAPILLON Study
PAPILLON is a randomized, open-label Phase 3 trial enrolling 308 newly diagnosed patients with advanced or metastatic NSCLC characterized by EGFR exon 20 insertion mutations.
-Primary endpoint: progression-free survival (RECIST v1.1, BICR-assessed)
-Key secondary endpoints: overall survival, overall response rate, time to symptomatic progression, PFS after the first subsequent therapy.
-Crossover design: Patients on chemotherapy alone were permitted to receive second-line RYBREVANT after progression, reflecting real-world treatment needs.
Johnson & Johnson continues to expand its oncology pipeline, positioning RYBREVANT as a cornerstone therapy in EGFR-mutated NSCLC.
JNJ has traded between $173.33 and $281.07 over the past year. The stock closed Friday's trading (September 11, 2026) at $265.58, down 0.29%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher Amid Inflation Data Release, Expectations Of Reopening Of Strait Of Hormuz
September 11, 2026 17:00 ET
Crude Oil Slumps Amid Rising Expectations Of An End To Hormuz Crisis, Profit-taking
September 11, 2026 14:41 ET
U.S. Dollar Advances Amid Oil-Linked Inflation Concerns, PPI Data Release
September 10, 2026 17:00 ET
U.S. Stocks Show Significant Rebound As Crude Oil Pulls Back Sharply
September 11, 2026 16:13 ET
Canadian Stocks Tumble Amid Increasing Concerns Of Oil-linked Inflation, Canada-U.S. Tariff War
September 10, 2026 16:32 ET
View More
Global Economics Weekly Update - Sep 07 – Sep 11, 2026
September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.
View More Videos
RELATED NEWS
Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials
Johnson & Johnson Receives CE Marking For ACUVUE OASYS MAX 2-Week Contact Lenses
FDA Approves J&J's IMAAVY For Warm Autoimmune Hemolytic Anemia
Johnson & Johnson's TECVAYLI-Daratumumab Combo Wins EU Approval For Relapsed Myeloma
Johnson & Johnson: FDA Grants Priority Review To SBLA For RYBREVANT FASPRO
Latest Updates on COVID-19
COVID-19 Sees Late-Summer Rise Across 49 US States
September 03, 2026 12:52 ET
COVID-19 Infections Rising In All 50 US States, CDC Data Shows
August 20, 2026 14:09 ET
COVID-19 Pandemic Linked To Higher Loneliness And Isolation In England, Study Finds
August 19, 2026 14:02 ET
View More
Editor's Pick
Most Read
Most Emailed
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Google To Invest 13 Bln Euros In Finland To Develop AI Infra, Clean Energy
September 09, 2026 09:11 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Orion180 Plans Up To $340 Mln IPO
September 09, 2026 08:04 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
HP Partners With Red Hat For AI Workloads; Shares Up
September 09, 2026 15:46 ET
Apple Unveils New AirPods And Apple Watch Lineup With Enhanced Audio, Health And AI Features
September 09, 2026 16:47 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Blackstone To Buy Flow Control Holdings From Audax For Undisclosed Terms
September 10, 2026 11:20 ET
Atlantic HPC Group To Go Public Via Aperture AC Merger
September 11, 2026 08:16 ET
SEALSQ H1 Loss Widens From Higher Expenses; Reaffirms FY26 Outlook
September 11, 2026 13:24 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Ageas Completes Sale Of 30.95% Maybank Ageas Stake To Maybank For EUR 1.1 Bln
September 11, 2026 01:43 ET
Holcim Invests In Cloud Cycle
September 09, 2026 03:16 ET
E79 Gold Mines Limited Full Year Sales Increase
September 09, 2026 01:00 ET
ASE Technology August Revenues Rise 34.6% Y-o-Y
September 09, 2026 03:18 ET
Everpure To Join S&P 500
September 09, 2026 01:09 ET
Victrex Plc Raises FY26 Underlying PBT View; Appoints Interim CFO; Stock Rises 12.8%
September 09, 2026 03:28 ET
Scientex Berhad Q4 Income Climbs
September 09, 2026 01:12 ET
Autohellas S.A. Reveals Fall In H1 Profit
September 09, 2026 03:33 ET
Chime To Acquire Stride Bank
September 09, 2026 01:26 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Antin Infrastructure Partners SAS Profit Drops In H1
September 09, 2026 01:29 ET
TENPOS HOLDINGS Co Ltd. Reveals Retreat In Q1 Profit
September 09, 2026 05:03 ET
Vallourec, Aramco Ink Agreement For Supply Of Oil Country Tubular Goods
September 09, 2026 01:45 ET
Editors Pick
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
J&J's RYBREVANT Plus Chemotherapy Sets New Benchmark In EGFR Exon 20 Insertion NSCLC Survival
By
TajSabreen Ahamed
✉
Published:
9/14/2026 4:09 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Johnson & Johnson (
JNJ
) announced that its bispecific antibody RYBREVANT, when combined with chemotherapy, achieved the longest reported median overall survival in patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC).
Patients receiving the combination achieved a median overall survival of 34.3 months, compared with 27.9 months for chemotherapy alone. Even though 76% of patients in the chemotherapy arm crossed over to second-line RYBREVANT after disease progression, the combination still extended survival by more than six months. These results represent the longest reported median OS in this population, nearly double historical survival expectations of 16-24 months, with five-year survival rates about 8%.
Durable Benefit and Differentiated Mechanism
RYBREVANT is the first-in-class bispecific antibody designed to dual-target EGFR and MET, two key drivers of tumor growth and treatment resistance, while also engaging the immune system. It is already approved across multiple EGFR- mutations NSCLC settings, including exon 20 insertion mutations.
Dr. Chul Kim of MedStar Georgetown University Hospital highlighted that the findings represent a meaningful advance for patients with limited treatment options, reinforcing RYBREVANT's role as a new standard in the first-line setting.
Detailed Overall Survival & Progression-Free Survival Findings
In the protocol-specified final analysis, RYBREVANT plus chemotherapy achieved:
-Median OS: 34.3 months vs. 27.9 months (HR 0.87; Cl 0.66-1.14; P=0.307)
-Adjusted OS (accounting for crossover): 43% reduction in risk of death (HR 0.57; Cl 0.39-0.82; nominal P=0.003)
-PFS2: Extended by more than 10 months (28.3 vs. 17.5 months; HR 0.59; P<0.0001)
-Treatment durability: 12% of patients remained on first-line therapy at cutoff vs. 0% in chemotherapy arm.
-Patient-reported outcomes: Delayed worsening of key lung cancer symptoms vs. chemotherapy alone.
These findings build on primary PAPILLON analysis, which previously demonstrated a clinically meaningful 60% improvement in progression-free survival, supporting global approvals.
Safety Profile
The safety profile of RYBREVANT plus chemotherapy was consistent with earlier studies, with no new safety signals observed.
Common treatment-related adverse events (greater than or equal to 30%) include paronychia, neutropenia, and rash.
About the PAPILLON Study
PAPILLON is a randomized, open-label Phase 3 trial enrolling 308 newly diagnosed patients with advanced or metastatic NSCLC characterized by EGFR exon 20 insertion mutations.
-Primary endpoint: progression-free survival (RECIST v1.1, BICR-assessed)
-Key secondary endpoints: overall survival, overall response rate, time to symptomatic progression, PFS after the first subsequent therapy.
-Crossover design: Patients on chemotherapy alone were permitted to receive second-line RYBREVANT after progression, reflecting real-world treatment needs.
Johnson & Johnson continues to expand its oncology pipeline, positioning RYBREVANT as a cornerstone therapy in EGFR-mutated NSCLC.
JNJ has traded between $173.33 and $281.07 over the past year. The stock closed Friday's trading (September 11, 2026) at $265.58, down 0.29%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Biotech Stocks Facing FDA Decision In July 2026
Latest Updates on Middle East War
U.S. Dollar Ticks Higher Amid Inflation Data Release, Expectations Of Reopening Of Strait Of Hormuz
September 11, 2026 17:00 ET
Crude Oil Slumps Amid Rising Expectations Of An End To Hormuz Crisis, Profit-taking
September 11, 2026 14:41 ET
U.S. Dollar Advances Amid Oil-Linked Inflation Concerns, PPI Data Release
September 10, 2026 17:00 ET
U.S. Stocks Show Significant Rebound As Crude Oil Pulls Back Sharply
September 11, 2026 16:13 ET
Canadian Stocks Tumble Amid Increasing Concerns Of Oil-linked Inflation, Canada-U.S. Tariff War
September 10, 2026 16:32 ET
View More
Global Economics Weekly Update - Sep 07 – Sep 11, 2026
September 11, 2026 16:26 ET
Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.
View More Videos
RELATED NEWS
Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials
Johnson & Johnson Receives CE Marking For ACUVUE OASYS MAX 2-Week Contact Lenses
FDA Approves J&J's IMAAVY For Warm Autoimmune Hemolytic Anemia
Johnson & Johnson's TECVAYLI-Daratumumab Combo Wins EU Approval For Relapsed Myeloma
Johnson & Johnson: FDA Grants Priority Review To SBLA For RYBREVANT FASPRO
Latest Updates on COVID-19
COVID-19 Sees Late-Summer Rise Across 49 US States
September 03, 2026 12:52 ET
COVID-19 Infections Rising In All 50 US States, CDC Data Shows
August 20, 2026 14:09 ET
COVID-19 Pandemic Linked To Higher Loneliness And Isolation In England, Study Finds
August 19, 2026 14:02 ET
View More
Editor's Pick
Most Read
Most Emailed
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Google To Invest 13 Bln Euros In Finland To Develop AI Infra, Clean Energy
September 09, 2026 09:11 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
Inditex H1 Profit Rises, Margin Flat, Backs FY26 Stable Margin View; Stock Drops
September 09, 2026 05:48 ET
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Orion180 Plans Up To $340 Mln IPO
September 09, 2026 08:04 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
HP Partners With Red Hat For AI Workloads; Shares Up
September 09, 2026 15:46 ET
Apple Unveils New AirPods And Apple Watch Lineup With Enhanced Audio, Health And AI Features
September 09, 2026 16:47 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Blackstone To Buy Flow Control Holdings From Audax For Undisclosed Terms
September 10, 2026 11:20 ET
Atlantic HPC Group To Go Public Via Aperture AC Merger
September 11, 2026 08:16 ET
SEALSQ H1 Loss Widens From Higher Expenses; Reaffirms FY26 Outlook
September 11, 2026 13:24 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Ageas Completes Sale Of 30.95% Maybank Ageas Stake To Maybank For EUR 1.1 Bln
September 11, 2026 01:43 ET
Holcim Invests In Cloud Cycle
September 09, 2026 03:16 ET
E79 Gold Mines Limited Full Year Sales Increase
September 09, 2026 01:00 ET
ASE Technology August Revenues Rise 34.6% Y-o-Y
September 09, 2026 03:18 ET
Everpure To Join S&P 500
September 09, 2026 01:09 ET
Victrex Plc Raises FY26 Underlying PBT View; Appoints Interim CFO; Stock Rises 12.8%
September 09, 2026 03:28 ET
Scientex Berhad Q4 Income Climbs
September 09, 2026 01:12 ET
Autohellas S.A. Reveals Fall In H1 Profit
September 09, 2026 03:33 ET
Chime To Acquire Stride Bank
September 09, 2026 01:26 ET
Sasol Agrees To Sell Nitrates Business To Enaex Africa; Retains 23% Stake
September 09, 2026 03:49 ET
Antin Infrastructure Partners SAS Profit Drops In H1
September 09, 2026 01:29 ET
TENPOS HOLDINGS Co Ltd. Reveals Retreat In Q1 Profit
September 09, 2026 05:03 ET
Vallourec, Aramco Ink Agreement For Supply Of Oil Country Tubular Goods
September 09, 2026 01:45 ET
Editors Pick
CPSC Recalls: 2.3 Mln Candy Bottles, Motorcycles, Dressers, Dual Fuel Ranges, Fire Spray Canisters
September 11, 2026 10:17 ET
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
September 11, 2026 07:40 ET
Macy's Stock Drops On Cautious Q3 View, Despite Positive Q2 Results, Raised FY26 Outlook
September 10, 2026 08:38 ET
Apple Unveils IPhone Duo, Its First Foldable IPhone
September 09, 2026 14:42 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。